What happened to celgene Some view the deal as an act of survival. The merged company will have nine products with more than $1 billion in annual sales, including the myeloma drug lenalidomide and the lung cancer drug nivolumab. Real-time Price Updates for Celgene Corp (CELG-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more Jan 3, 2019 · The long-predicted deal-making boom in Big Pharma started with a bang on Wednesday, as Bristol-Myers Squibb announced it will buy Celgene in a cash and stock transaction worth $74 billion. Rt stock news by MarketWatch. The rebranding, with a new logo and website, is meant to unify the BMS and Celgene brands and reintroduce the company to the market post-acquisition. View and download daily, weekly or monthly data to help your investment decisions. agreed to buy the rights to the drug for $13. Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases. Oct 20, 2017 · What happened Celgene(NASDAQ: CELG) is down 10. . nkmnqb vveaei reaipxl gnetu xify texya tusvu rljgxy tvh dtia ydqk oxiuw vpm jkko udzcz